跳至主要内容
临床试验/ACTRN12610000438055
ACTRN12610000438055已完成1 期

A Randomised, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Efficacy of Recombinant Human ß Defensin 2 (rHuB[beta]D2 cream) in the Treatment of Staphylococcus aureus and other Infections in the Skin of Patients with Atopic Dermatitis

Planton GmbH0 个研究点目标入组 36 人开始时间: 2010年5月28日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
Planton GmbH
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
All

入选标准

  • Currently suffering from atopic dermatitis (AD) with a primary diagnosis of AD at least 12 weeks prior to inclusion into the study.
  • With a SCORAD between 20 and 50 (i.e., mild to moderate AD).
  • Diagnosed with disseminated symmetric dermatitis.
  • Colonisation of lesional skin with Staphylococcus aureus (and probably other micro-organisms)

排除标准

  • Current use of the following therapeutic interventions at the affected areas of the skin and a zone of 4 cm around the affected areas:
  • - Any kind of topical glucocorticosteroidproducts
  • - Cyclosporine or other calcineurin inhibitors
  • - Topical antibiotics or antiseptics (also in ointments)

研究者

发起方
Planton GmbH

相似试验